Arcellx Inc.
NEWS
Gaithersburg, Maryland-based Arcellx, Inc. unveiled its ticker symbol on the Nasdaq Friday, hitting the market at a cool $15 per share.
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
Arcellx, based in Gaithersburg, Maryland, closed on a Series C financing round worth $115 million.
The company plans to use the funds raised to advance the ARC-T and sparX programs, including development of a bivalent BCMA-targeted therapy in multiple myeloma and a CD123-targeted treatment in acute myeloid leukemia.
JOBS
IN THE PRESS